Skip to content

A CLINICAL STUDY TO EVALUATE THE EFFICACY OF ALKALI PREPARATION MADE OUT OF SESAME PLANT IN MANAGEMENT OF ENLARGED PROSTATE

A CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF TILANALA KSHARA IN THE MANAGEMENT OF VATASHTEELA vis-a-vis BENIGN PROSTATIC HYPERPLASIA[BPH]

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036137
Enrollment
50
Registered
2021-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Tilanala kshara: 500mg twice daily after food with luke warm water for total 30 days Control Intervention1: Gokshuradi guggulu: 3gm daily ain 3 equally divided doses after food for tot

Sponsors

Government Ayurveda medical college Mysore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects belonging to age group of 40 to 70 2. USG of bladder suggestive of residual urine volume upto 100ml. 3. Mild to moderate grades of BPH with prostate weight upto 75 gms 4. Both fresh and treated cases of vatashteela vis-à-vis BPH

Exclusion criteria

Exclusion criteria: 1. Subjects suffering from malignancy, congenital deformities of urogenital tract or any other pelvic pathologies 2. Chronic UTI, urinary calculus, renal failure, urinary stricture 3. Systemic diseases like uncontrolled Diabetes mellitus( RBS range above 300mg/dl), Hypertension(stage 3 or above), Tuberculosis, paralysis, parkinsonism and other disorders that may interfere with the present intervention 4. Subjects with immune compromised conditions like HIV 5. Subjects with USG findings suggestive of Hydroureteronephrosis 6. Subjects unfit for paneeya kshara intake like acid peptic disorders etc

Design outcomes

Primary

MeasureTime frame
Reduction in size of prostate in USG abdomen and pelvisTimepoint: Baseline 2 weeks 4 weeks

Secondary

MeasureTime frame
Releif for patient as per IPSS scalingTimepoint: 0th , 15th and 31 st days

Countries

India

Contacts

Public ContactRahul Ravi P

Government Ayurveda Medical College Mysuru

rahulrv999@gmail.com08592816488

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026